Belleric Myrobalan and Reduced Adherence Attrition

Doses used in studies

mg/day: 500 (median 500, IQR 500–500) — 1 study

Safety in these studies

Overall tolerabilityReported
Terminalia bellerica 500 mg/day, a novel xanthine oxidase inhibitor (XOI) made of natural fruit extracts, and topiroxostat ≥ 80 mg/day, an XOI used mostly in Japan, could be new effective options for lowering the occurrence of adherence attrition events.
from: Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Ba

1 of 1 paper

Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.

2020-01-21
Systematic Review · n = 401
Clinical rheumatology 39(5)
- Yu-Jiun Lin
- Shiyng-Yu Lin
- Chang-Hsien Lin
- Sen-Te Wang
- Shy-Shin Chang

PubMed: 31965378
DOI: 10.1007/s10067-019-04893-8

1 Insight on

Reduced Adherence Attrition

High evidence
Clinical

terminalia bellerica 500 mg/day, a novel xanthine oxidase inhibitor (XOI) made of natural fruit extracts, ... could be new effective options for lowering the occurrence of adherence attrition events.

Effect: Beneficial
Effect size: Small
Significant: Yes
Dose: 500 mg/day